Mismatch responses and deviance detection in N-methyl-D-aspartate (NMDA) receptor hypofunction and developmental models of schizophrenia

Biological Psychology

Volumn 116, Issue , 2016, Pages 75-81

  Harms, Lauren ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adaptation; Animal model; Deviance detection; Mismatch negativity (MMN); N methyl D aspartate (NMDA) receptor; Schizophrenia

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ARTICLE; BRAIN DEVELOPMENT; EVENT RELATED POTENTIAL; EXPERIMENTAL MODEL; HUMAN; MENTAL FUNCTION; MISMATCH NEGATIVITY; MISMATCH RESPONSE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; ANIMAL; ANIMAL MODEL; AUDITORY EVOKED POTENTIAL; AUDITORY STIMULATION; BRAIN; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RAT; REACTION TIME;

ACOUSTIC STIMULATION; ANIMALS; BRAIN; EVOKED POTENTIALS, AUDITORY; HUMANS; MICE; MODELS, ANIMAL; RATS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84961411301     PISSN: 03010511     EISSN: 18736246     Source Type: Journal    
DOI: 10.1016/j.biopsycho.2015.06.015     Document Type: Article

References (85)

1. Alho K. Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNm) elicited by sound changes. Ear and Hear 1995, 16:38-51.
2. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. Journal of Pharmacology and Experimental Therapeutics 1999, 290:1393-1408.
3. Baldeweg T., Klugman A., Gruzelier J., Hirsch S.R. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophrenia Research 2004, 69:203-217.
4. Baldeweg T., Wong D., Stephan K.E. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. International Journal of Psychophysiology 2006, 59:49-58.
5. Becker A., Peters B., Schroeder H., Mann T., Huether G., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Progress in NeuroPsychopharmacology and Biological Psychiatry 2003, 27:687-700.
6. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33:2175-2186.
7. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 2008, 64:361-368.
8. Bodatsch M., Brockhaus-Dumke A., Klosterkotter J., Ruhrmann S. Forecasting psychosis by event-related potentials-systematic review and specific meta-analysis. Biological Psychiatry 2015, 77:951-958.
9. Bresnahan M., Schaefer C.A., Brown A.S., Susser E.S. Prenatal determinants of schizophrenia: what we have learned thus far. Epidemiology Psychiatry Society 2005, 14:194-197.
10. Brown A.S. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Developmental Neurobiology 2012, 72:1272-1276.
11. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. American Journal of Psychiatry 2010, 167:261-280.
12. Cabungcal J.H., Counotte D.S., Lewis E.M., Tejeda H.A., Piantadosi P., Pollock C., et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 2014, 83:1073-1084.
13. Cannon M., Jones P.B., Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. American Journal of Psychiatry 2002, 159:1080-1092.
14. Cilia J., Reavill C., Hagan J.J., Jones D.N. Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats. Psychopharmacology (Berlin) 2001, 156:327-337.
15. Corlett P.R., Honey G.D., Fletcher P.C. From prediction error to psychosis: ketamine as a pharmacological model of delusions. Journal of Psychopharmacology 2007, 21:238-252.
16. Cull-Candy S.G., Leszkiewicz D.N. Role of distinct NMDA receptor subtypes at central synapses. Science STKE 2004, re16.
17. Dean K., Murray R.M. Environmental risk factors for psychosis. Dialogues in Clinical Neuroscience 2005, 7:69-80.
18. Domino E.F., Luby E.D. Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophrenia Bulletin 2012, 38:914-919.
19. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., et al. Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130:1146-1158.
20. Dunbar G., Boeijinga P.H., Demazieres A., Cisterni C., Kuchibhatla R., Wesnes K., et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berlin) 2007, 191:919-929.
21. Ehrlichman R.S., Maxwell C.R., Majumdar S., Siegel S.J. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. Journal of Cognitive Neuroscience 2008, 20:1403-1414.
22. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 2000, 11:223-233.
23. Fabricius K., Helboe L., Fink-Jensen A., Wortwein G., Steiniger-Brach B., Sotty F. Increased dopaminergic activity in socially isolated rats: an electrophysiological study. Neuroscience Letters 2010, 482:117-122.
24. Featherstone R.E., Shin R., Kogan J.H., Liang Y., Matsumoto M., Siegel S.J. Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: implications for schizophrenia prodromal population. Neurobiology of Disease 2014, 73C:289-295.
25. Fone K.C., Porkess M.V. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neuroscience Biobehavioral Reviews 2008, 32:1087-1102.
26. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
27. Geyer M.A., Wilkinson L.S., Humby T., Robbins T.W. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biological Psychiatry 1993, 34:361-372.
28. Giard M.H., Perrin F., Pernier J., Bouchet P. Brain generators implicated in the processing of auditory stimulus deviance: a topographic event-related potential study. Psychophysiology 1990, 27:627-640.
29. Harkrider A.W., Hedrick M.S. Acute effect of nicotine on auditory gating in smokers and non-smokers. Hearing Research 2005, 202:114-128.
30. Harms L., Fulham W.R., Todd J., Budd T.W., Hunter M., Meehan C., et al. Mismatch negativity (MMN) in freely-moving rats with several experimental controls. PLoS One 2014, 9:e110892.
31. Harms L., Michie P.T., Naatanen R. Criteria for determining whether mismatch responses exist in animal models: focus on rodents. Biological Psychology 2016, 116:28-35.
32. Jacobsen T., Schroger E. Is there pre-attentive memory-based comparison of pitch?. Psychophysiology 2001, 38:723-727.
33. Jacobsen T., Schröger E. Measuring duration mismtach negativity. Clinical Neurophysiology 2003, 114:1133-1143.
34. Jacobsen T., Schröger E., Horenkamp T., Winkler I. Mismatch negativity to pitch change: varied stimulus proportions in controlling effects of neural refractoriness on human auditory event-related brain potentials. Neuroscience Letters 2003, 344:79-82.
35. Javitt D.C., Grochowski S., Shelley A.M., Ritter W. Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalography and Clinical Neurophysiology 1998, 108:143-153.
36. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophrenia Bulletin 2012, 38:958-966.
37. Jung F., Stephan K.E., Backes H., Moran R., Gramer M., Kumagai T., et al. Mismatch responses in the awake rat: evidence from epidural recordings of auditory cortical fields. PLoS One 2013, 8:e63203.
38. Knott V., Shah D., Millar A., McIntosh J., Fisher D., Blais C., et al. Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait. Frontiers in Pharmacology 2012, 3:172.
39. Knott V.J., Bolton K., Heenan A., Shah D., Fisher D.J., Villeneuve C. Effects of acute nicotine on event-related potential and performance indices of auditory distraction in nonsmokers. Nicotine Tobacco Research 2009, 11:519-530.
40. Korostenskaja M., Nikulin V.V., Kicic D., Nikulina A.V., Kahkonen S. Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Research Bulletin 2007, 72:275-283.
41. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
42. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience and Biobehavioral Reviews 2005, 29:1021-1034.
43. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
44. Le Strat Y., Ramoz N., Gorwood P. The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (G×E) in schizophrenia. Current Molecular Medicine 2009, 9:506-518.
45. Light G.A., Swerdlow N.R. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Annals of the New York Academy of Sciences 2015, 1344:105-119.
46. Lin H., Vicini S., Hsu F.C., Doshi S., Takano H., Coulter D.A., et al. Axonal alpha7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:16661-16666.
47. Liu Y., Ford B.D., Mann M.A., Fischbach G.D. Neuregulin-1 increases the proliferation of neuronal progenitors from embryonic neural stem cells. Developmental Biology 2005, 283:437-445.
48. Maess B., Jacobsen T., Schroger E., Friederici A.D. Localizing pre-attentive auditory memory-based comparison: magnetic mismatch negativity to pitch change. Neuroimage 2007, 37:561-571.
49. Malaspina D., Corcoran C., Kleinhaus K.R., Perrin M.C., Fennig S., Nahon D., et al. Acute maternal stress in pregnancy and schizophrenia in offspring: a cohort prospective study. BMC Psychiatry 2008, 8:71.
50. Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009, 136:1017-1031.
51. Martin L.F., Davalos D.B., Kisley M.A. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tobacco Research 2009, 11:698-706.
52. McDonald C., Murray R.M. Early and late environmental risk factors for schizophrenia. Brain Research Brain Research Reviews 2000, 31:130-137.
53. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Archives of General Psychiatry 2010, 67:889-894.
54. McGrath J.J., Feron F.P., Burne T.H.J., Mackay-Sim A., Eyles D.W. The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Annals of Medicine 2003, 35:86-93.
55. Michie P.T., Innes-Brown H., Todd J., Jablensky A.V. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biological Psychiatry 2002, 52:749-758.
56. Näätänen R. Attention and brain function 1992, Lawrence Erlbaum Associates, Hillsdale, NJ.
57. Naatanen R., Alho K. Generators of electrical and magnetic mismatch responses in humans. Brain Topography 1995, 7:315-320.
58. Naatanen R., Jacobsen T., Winkler I. Memory-based or afferent processes in mismatch negativity (MMN): a review of the evidence. Psychophysiology 2005, 42:25-32.
59. Naatanen R., Tervaniemi M., Sussman E., Paavilainen P., Winkler I. Primitive intelligence in the auditory cortex. Trends in Neuroscience 2001, 24:283-288.
60. Nakamura T., Michie P.T., Fulham W.R., Todd J., Budd T.W., Schall U., et al. Epidural auditory event-related potentials in the rat to frequency and duration deviants: evidence of mismatch negativity. Frontiers in Psychology 2011, 2:367.
61. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophrenia Bulletin 2011, 37:484-492.
62. Opler M.G., Susser E.S. Fetal environment and schizophrenia. Environmental Health Perspectives 2005, 113:1239-1242.
63. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry 2012, 17:1228-1238.
64. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Annual Review of Neuroscience 1999, 10:59-90.
65. Sato Y., Yabe H., Hiruma T., Sutoh T., Shinozaki N., Nashida T., et al. The effect of deviant stimulus probability on the human mismatch process. Neuroreport 2000, 11:3703-3708.
66. Schmidt A., Diaconescu A.O., Kometer M., Friston K.J., Stephan K.E., Vollenweider F.X. Modeling ketamine effects on synaptic plasticity during the mismatch negativity. Cerebral Cortex 2012.
67. Shannon Weickert C., Fung S.J., Catts V.S., Schofield P.R., Allen K.M., Moore L.T., et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Molecular Psychiatry 2013, 18:1185-1192.
68. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biological Psychiatry 1991, 30:1059-1062.
69. Sivarao D.V., Chen P., Yang Y., Li Y.W., Pieschl R., Ahlijanian M.K. NR2B antagonist CP-101,606 abolishes pitch-mediated deviance detection in awake rats. Frontiers in Psychiatry 2014, 5:96.
70. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of neuroleptic-free schizophrenics: evidence on reversible up-regulation by typical neuroleptics. Journal of Neurochemistry 1998, 71:2454-2464.
71. Tikhonravov D., Neuvonen T., Pertovaara A., Savioja K., Ruusuvirta T., Naatanen R., et al. Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Research 2008, 1203:97-102.
72. Tikhonravov D., Neuvonen T., Pertovaara A., Savioja K., Ruusuvirta T., Naatanen R., et al. Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats. Neuroscience 2010, 167:1175-1182.
73. Todd J., Harms L., Schall U., Michie P.T. Mismatch negativity: translating the potential. Frontiers in Psychiatry 2013, 4:171.
74. Todd J., Michie P.T., Budd T.W., Rock D., Jablensky A.V. Auditory sensory memory in schizophrenia: inadequate trace formation. Psychiatry Research 2000, 96:99-115.
75. Todd J., Michie P.T., Jablensky A.V. Association between reduced duration mismatch negativity (MMN) and raised temporal discrimination thresholds in schizophrenia. Clinical Neurophysiology 2003, 114:2061-2070.
76. Todd J., Michie P.T., Schall U., Karayanidis F., Yabe H., Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biological Psychiatry 2008, 63:58-64.
77. Todd J., Michie P.T., Schall U., Ward P.B., Catts S.V. Mismatch negativity (MMN) reduction in schizophrenia-impaired prediction-error generation, estimation or salience?. International Journal of Psychophysiology 2012, 83:222-231.
78. Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacological Reviews 2010, 62:405-496.
79. Tseng K.Y., Chambers R.A., Lipska B.K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behavioural Brain Research 2009, 204:295-305.
80. Ulanovsky N., Las L., Farkas D., Nelken I. Multiple time scales of adaptation in auditory cortex neurons. Journal of Neuroscience 2004, 24:10440-10453.
81. Ulanovsky N., Las L., Nelken I. Processing of low-probability sounds by cortical neurons. Nature Neuroscience 2003, 6:391-398.
82. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophrenia Research 2005, 76:1-23.
83. Witten L., Oranje B., Mork A., Steiniger-Brach B., Glenthoj B.Y., Bastlund J.F. Auditory sensory processing deficits in sensory gating and mismatch negativity-like responses in the social isolation rat model of schizophrenia. Behavioural Brain Research 2014, 266:85-93.
84. Young J.W., Light G.A., Marston H.M., Sharp R., Geyer M.A. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One 2009, 4:e4227.
85. Zoladz P.R., Campbell A.M., Park C.R., Schaefer D., Danysz W., Diamond D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacology Biochemistry and Behavior 2006, 85:298-306.